Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dennis Andress"'
Autor:
Kim M. Gooding, Chrysta Lienczewski, Massimo Papale, Niina Koivuviita, Marlena Maziarz, Anna-Maria Dutius Andersson, Kanishka Sharma, Paola Pontrelli, Alberto Garcia Hernandez, Julie Bailey, Kay Tobin, Virva Saunavaara, Anna Zetterqvist, David Shelley, Irvin Teh, Claire Ball, Sapna Puppala, Mark Ibberson, Anil Karihaloo, Kaj Metsärinne, Rosamonde E. Banks, Peter S. Gilmour, Michael Mansfield, Mark Gilchrist, Dick de Zeeuw, Hiddo J. L. Heerspink, Pirjo Nuutila, Matthias Kretzler, Matthew Welberry Smith, Loreto Gesualdo, Dennis Andress, Nicolas Grenier, Angela C. Shore, Maria F. Gomez, Steven Sourbron, for the BEAt-DKD consortium
Publikováno v:
BMC Nephrology, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value
Externí odkaz:
https://doaj.org/article/e94cbf7fb6ec48ce9d18b5b1e307048f
Autor:
Walid M. Awni, John J. Brennan, Chih-Wei Lin, Nael M. Mostafa, Cheri E. Klein, Dennis Andress
Publikováno v:
Clinical Therapeutics. 40:242-251
Purpose The objective of the current analyses was to characterize the pharmacokinetic properties of atrasentan and the exposure-response relationships for the efficacy end point, urinary albumin to creatinine ratio (UACR), and the treatment-emergent
Autor:
Blai Coll, Mark Houser, Dennis Andress, Dick de Zeeuw, Pablo E. Pergola, Yili Pritchett, Donald E. Kohan, Hirofumi Makino, Sheldon W. Tobe, Hiddo J.L. Heerspink, Hans-Henrik Parving, Robert S. Busch, Ricardo Correa-Rotter, Vlado Perkovic, John J. Brennan, Robert D. Toto, Giuseppe Remuzzi, David J. Webb
Publikováno v:
Webb, D J, Coll, B, Heerspink, H J L, Andress, D, Pritchett, Y, Brennan, J J, Houser, M, Correa-Rotter, R, Kohan, D, Makino, H, Perkovic, V, Remuzzi, G, Tobe, S W, Toto, R, Busch, R, Pergola, P, Parving, H-H & de Zeeuw, D 2017, ' Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy : A Randomized, Double-Blind, Placebo-Controlled Trial ', Drugs, pp. 441-448 . https://doi.org/10.1007/s40268-017-0201-0
Drugs in R&D, 17(3), 441-448
Drugs in R&D
Drugs in R&D, 17(3), 441-448
Drugs in R&D
BACKGROUND: Fluid retention is a common adverse event in patients who receive endothelin (ET) receptor antagonist therapy, including the highly selective ETA receptor antagonist, atrasentan.OBJECTIVE: We performed longitudinal assessments of thoracic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6fc266a8c2e6a85c8f83451f4d65c3
https://www.pure.ed.ac.uk/ws/files/43186284/10.1007_s40268_017_0201_0.pdf
https://www.pure.ed.ac.uk/ws/files/43186284/10.1007_s40268_017_0201_0.pdf
Publikováno v:
Nephrology Dialysis Transplantation, 28(9), 2260-2268. Oxford University Press
Nephrology Dialysis Transplantation
Nephrology Dialysis Transplantation
Background Chronic kidney disease (CKD) is associated with elevations in serum phosphate, calcium–phosphorus product and bone-specific alkaline phosphatase (BAP), with attendant risks of cardiovascular and bone disorders. Active vitamin D can suppr
Autor:
Michelle J, Pena, Dick, de Zeeuw, Dennis, Andress, John J, Brennan, Ricardo, Correa-Rotter, Blai, Coll, Donald E, Kohan, Hirofumi, Makino, Vlado, Perkovic, Giuseppe, Remuzzi, Sheldon W, Tobe, Robert, Toto, Hans-Henrik, Parving, Shoba, Sharma, Tom, Corringham, Kumar, Sharma, Hiddo J L, Heerspink
Publikováno v:
Diabetes, obesitymetabolism. 19(5)
We assessed the effect of atrasentan therapy on a pre-specified panel of 13 urinary metabolites known to reflect mitochondrial function in patients with diabetic kidney disease. This post-hoc analysis was performed using urine samples collected durin
Publikováno v:
University of Groningen
The disclosure relates to methods of treating chronic kidney disease and diabetic nephropathy using predictors of fluid retention to minimize the risk of adverse events. The methods disclosed are particularly useful in treatments involving endothelin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ff26429d48b02e6e889acf7bf329a2c6
https://research.rug.nl/en/publications/6ab210bf-75f3-477c-8fbe-fbf4487b1510
https://research.rug.nl/en/publications/6ab210bf-75f3-477c-8fbe-fbf4487b1510
Autor:
Masazumi Matsumura, Ami S. Bhatt, Dennis Andress, Nigel Clegg, Thomas K. Takayama, Charles S. Craik, Peter S. Nelson
Publikováno v:
Prostate; Jan2005, Vol. 62 Issue 1, p1-13, 13p
Publikováno v:
Kidney International. 25(2):445-452
Parathyroid hormone and bone histology: Response to hypocalcemia in osteitis fibrosa. The parathyroid hormone (PTH) response to hypocalcemia was studied in 18 hemodialysis patients with osteitis fibrosa, and the relationship with PTH and bone histolo
Autor:
Anh The Nong, Dennis Andress, Tim Hulsen, Ruth Andrea Seeler, Barbara J. Bowers, Henry A. Peters, Arthur S. Leon, John P. Conomy, Michael F. Heiman, Robert W. Barnes, Joseph Upton
Publikováno v:
Postgraduate Medicine. 67:43-48
Publikováno v:
Kidney international. 24(3)
Parathyroid hormone response to hypocalcemia in hemodialysis patients with osteomalacia. The parathyroid hormone response to hypocalcemia was investigated in hemodialysis patients with osteomalacia and compared to those with osteitis fibrosa. Hypocal